Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase: Analysis of a Phase 1/2 Study

Using data from a phase I/II clinical trial of enasidenib in patients with relapsed/refractory acute myeloid leukemia, researchers created an algorithm to identify and treat the signs and symptoms of IDH2 inhibitor–associated differentiation syndrome.

JAMA Oncology